87394-55-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Chloropyridin-2-yl)piperazine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to form a wide range of bioactive compounds. Its unique structure allows for the creation of molecules with potential therapeutic effects, making it a valuable asset in the development of new drugs.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(3-Chloropyridin-2-yl)piperazine is utilized as a research tool to explore its potential in treating various diseases and disorders. Its reactivity and structural features facilitate the design and synthesis of novel compounds with specific biological activities.
Used in Drug Discovery:
1-(3-Chloropyridin-2-yl)piperazine is employed in drug discovery processes to identify new lead compounds with therapeutic potential. Its unique chemical properties enable the development of innovative drug candidates that can address unmet medical needs.

InChI:InChI=1/C9H12ClN3/c10-8-2-1-3-12-9(8)13-6-4-11-5-7-13/h1-3,11H,4-7H2

Upstream product

• 110-85-0 piperazine 
• 2402-77-9 2,3-dichloro-pyridine 
• 71-36-3 butan-1-ol 
• 683240-45-1 tert-butyl 4-(3-chloropyridin-2-yl)piperazine-1-carboxylate 

Downstream Products

• 393514-24-4 N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide 
• 1202247-73-1 C₂₂H₂₀ClN₃O₂ 
• 1202247-63-9 C₂₀H₂₄ClN₃O₂ 
• 1202247-69-5 C₁₆H₁₅Cl₂N₃O₂ 
• 1202247-71-9 C₁₆H₁₅Cl₂N₃O₂ 

Relevant academic research and scientific papers

PYRROLE mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

PYRROLE mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Substituted indole compound and method and use thereof

The invention provides a new indole compound, pharmaceutically acceptable salts and medicinal preparations thereof, and a use of the new indole compound in selective inhibition of 5-hydroxytryptamine reuptake and /or excitation of a 5-HT1A receptor. The invention also relates to medicinal compositions comprising the compounds, and a method for treating the central nervous system dysfunction of mammals, especially humans by using the medicinal compositions.

Synthesis of Analogues of BCTC Incorporating a Pyrrolidinyl Linker and Biological Evaluation as Transient Receptor Potential Vanilloid 1 Antagonists

A series of novel pyrrolidinyl linker TRPV1 antagonists were prepared in an effort to lower the hyperthermic side-effects of first-generation antagonist BCTC. These compounds were investigated for antagonism of hTRPV1 activation by capsaicin and acid in vitro. Preliminary results suggested the compounds 10a, 10b, 10c and 10j had favorable TRPV1 antagonism activity. In further studies in vivo, 10b, comparable to BCTC, showed potent analgesic activity in capsaicin-induced and heat-induced pain models. In addition, 10b indicated a reduced risk of body temperature elevation. All of these demonstrated that 10b can be considered as a safe candidate for the further development of analgesic drugs. A series of novel pyrrolidinyl linker TRPV1 antagonists were prepared in an effort to lower the hyperthermic side-effects of first-generation antagonist BCTC. These compounds were investigated for antagonism of hTRPV1 activation by capsaicin and acid in vitro. Preliminary results suggested the compounds 10a, 10b, 10c and 10j had favorable TRPV1 antagonism activity. In further studies in vivo, 10b, comparable to BCTC, showed potent analgesic activity in capsaicin-induced and heat-induced pain models. In addition, 10b indicated a reduced risk of body temperature elevation. All of these demonstrated that 10b can be considered as a safe candidate for the further development of analgesic drugs.

Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor

Substituted cyclic carboxamide and urea compounds, a process for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for the treatment and/or inhibition of pain and other conditions mediated by the vanilloid receptor 1.

COMPOUNDS AS TRVP1 BLOCKERS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF

A kind of new compounds, and their pharmaceutically acceptable salts, and hydrates are disclosed. The pharmaceutical composition thereof is also provided. And also are the medical uses of the compounds, pharmaceutically acceptable salts, hydrates and the

GLYCINE COMPOUND

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

NOVEL VANILLOID RECEPTOR MODULATORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention pertains to novel vanilloid receptor modulators of general formula I, process for their preparation, and pharmaceutical compositions containing them. These novel vanilloid receptor modulators are valuable agents for preventing, ameliorating, or treating vanilloid receptor mediated diseases and are useful, e.g., for the treatment of acute pain, chronic pain, nociceptive pain, neuropathic pain, post? operative pain, dental pain, cancer pain, or pain due to retinopathy, stroke, urinary incontinence, inflammatory bowel disease, irritation of skin, dermatitis and muscle spasms. (I) General Formula(I)

ORGANOSILICON COMPOUNDS AND THEIR USE AS THE MODULATORS OF THE TRPV1 RECEPTOR

A compound having the Formula (1): wherein: X1, X2, X3 and X4 independently represent CH or N; R1, R2 and R3 independently represent C1-6 alkyl, C3-8 cycloalkyl or C3-8 cycloalky IC1-6alkyl, each of which groups may be optionally substituted with one or more substituents independently selected from halogen and haloC1-6 alkyl; R4, R5, R6, R7, R8 and R9 independently represent H, C1-6 alkyl, C3-8 cycloalkyl or -QI-OR14, or R4 and R9 may join to form a bridging C1-6 alkylene chain; R10 represents aryl or heteroaryl, each of which may be optionally substituted by one or more substituents, independently selected from halogen, C1-6 alkyl, haloC1-6 alkyl, hydroxyC1-6alkyl, haloC1-6 alkoxy, cyano, -Q2-CO2R12, -Q2-COR12, -Q2-CONR12R13, -Q2-OR12, -Q2-NR12Rn, -Q2-NR12SO2R13, -Q2- NR12COR13, -Q2-SO2NR12R13, -Q2-S(O)mR12, -Y-aryl, -Y-heteroaryl, -Y-C3-8 cycloalkyl and -Y-heterocyclyl; Q1 and Q2 independently represent a covalent bond, C1-6 alkylene, or 1-6 alkylene substituted with hydroxy; R12 and R13 independently represent a H atom, or a C1-6 alkyl or C3-8 cycloalkyl group, in which each group may be optionally substituted with one or more C1-6 alkoxy; or when R12 and R13 are attached to the same nitrogen atom they may join to form a nitrogen containing heterocyclyl ring, which may be optionally substituted with one or more substituents independently selected from C1-6 alkyl and C1-6 alkoxy; R14 represents a H atom, or a C1-6 alkyl or C3-8 cycloalkyl group, in which each group may be optionally substituted with one or more C1-6 alkoxy; Y represents a covalent bond, C1-6 alkylene, or -O-. m represents 0, 1 or 2; R11, which is optionally present and may be attached to any available carbon atom X1 to X4 instead of H, represents halogen, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, cyano or C1-6 alkyl which may be optionally substituted with one or more substituents independently selected from halogen, haloC1-6 alkyl and OR16; q represents 0, 1 or 2; W represents -(CH2)n-, which may be optionally substituted with one or more substituents independently selected from C1-6 alkyl, C3-8 cycloalkyl and -Q3-OR15; n represents 1 or 2; Q3 represents a covalent bond or C1-6 alkylene; R15 represents H, C1-6 alkyl, or C3-8 cycloalkyl; R16 is as defined for R14; or a pharmaceutically acceptable salt or ester thereof. Uses of the compounds as modulators of the TrpVl receptor are also disclosed.

Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands

The evaluation of a series of piperazinyl carbamates and ureas, designed on the basis of previously reported TRPV1 antagonists and FAAH inhibitors, led to the identification of some 'dual-action' compounds targeting both FAAH and TRPV1 or TRPA1 receptors.